The 2017/18 influenza season in Canada has been characterised by co-circulation of influenza A(H3N2) and B(Yamagata) viruses, the latter unusual so early in the season \[[@r1]\]. Most European countries are also experiencing simultaneous influenza A and B epidemics, with B(Yamagata) predominating \[[@r2]\], whereas the United States (US) has experienced a substantial epidemic due predominantly to influenza A(H3N2) \[[@r3]\].

The 2017/18 trivalent influenza vaccine (TIV) includes influenza A/Hong Kong/4801/2014(H3N2)-like (clade 3C.2a) and B/Brisbane/60/2008(Victoria-lineage)-like (clade 1A) antigens. The quadrivalent influenza vaccine (QIV) contains an additional influenza B/Phuket/3073/2013(Yamagata-lineage)-like (clade 3) antigen. The same components were included in the 2016/17 northern and 2017 southern hemisphere vaccines \[[@r4]\].

Low vaccine effectiveness (VE) for the 2017/18 season has been anticipated following the interim report from Australia indicating VE of just 10% during its 2017 influenza A(H3N2) epidemic \[[@r5]\]. In the context of exclusive QIV use, Australia reported higher VE of 57% against co-circulating influenza B viruses \[[@r5]\]. Here we report interim 2017/18 VE estimates for influenza A(H3N2) and influenza B from participating provinces of the Canadian Sentinel Practitioner Surveillance Network (SPSN), where QIV comprised less than one third of vaccine doses distributed overall through the publicly funded campaign.

Vaccine effectiveness evaluation
================================

VE was derived using a test-negative design \[[@r6]-[@r9]\]. Nasal/nasopharyngeal specimens and epidemiological data were collected from patients presenting within 7 days of onset of influenza-like illness (ILI) to community-based sentinel practitioners in Alberta, British Columbia, Ontario and Quebec. ILI was defined as acute onset of fever and cough and at least one other symptom including sore throat, myalgia, arthralgia or prostration. Fever was not a requirement for elderly adults 65 years of age and older. Vaccination status was based on patient and/or practitioner reporting of 2017/18 vaccination at least 2 weeks before symptom onset; patients vaccinated less than 2 weeks before onset or with unknown vaccination status/timing were excluded. Institutional review boards in each province provided ethical approval for the study.

Specimens collected from week 45 (starting 5 November 2017) to week 3 (ending 20 January 2018) were tested for influenza type/subtype by real-time RT-PCR at provincial public health reference laboratories. Sanger sequencing of the viral haemagglutinin gene was undertaken on a subset of original patient specimens collected up to 13 January 2018 to assess the contribution of genetic clades to VE estimates.

Odds ratios (OR) comparing test-positivity for influenza A(H3N2) or B between vaccinated and unvaccinated participants who were at least 1-year-old were calculated using logistic regression, adjusted for relevant covariates. VE was derived as (1 − OR) × 100%.

Virological findings
====================

Among 1,408 eligible specimens, 689 (49%) tested positive for influenza, including 338 (49%) influenza A and 351 (51%) influenza B ([Figure 1](#f1){ref-type="fig"}). Among the 330 (98%) subtyped influenza A viruses, 302 (92%) were A(H3N2) and 28 (8%) were A(H1N1)pdm09.
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Most sequenced influenza A(H3N2) viruses belonged to genetic clade 3C.2a (213/229; 93%) and of these most (204/213; 96%) belonged to a single genetic subgroup of 3C.2a (denoted subgroup 3 by [nextflu.o[rg]{.ul}](http://nextflu.org/h3n2/3y/) \[[@r10]\]), bearing antigenic site A substitutions T131K and R142K and antigenic site E substitution R261Q ([Table 1](#t1){ref-type="table"}). Overall 89% of influenza A(H3N2) viruses belonged to clade 3C.2a subgroup 3, which is similar to other surveillance observations from Canada (83%) ([Figure 2](#f2){ref-type="fig"}) and to recent reports from Europe \[[@r11]\]. However, this profile for the 2017/18 season is different from that found by the Canadian SPSN during 2016/17 or by Australia during its 2017 epidemic, when a greater mix of genetic variants contributed to interim analyses and only 14% and 7%, respectively, of influenza A(H3N2) viruses belonged to subgroup 3 ([Figure 2](#f2){ref-type="fig"}).

###### Virological profile of influenza specimens contributing to interim 2017/18 vaccine effectiveness evaluation based on Sanger sequencing, Canadian Sentinel Practitioner Surveillance Network, 5 November 2017--13 January 2018 (n = 462)

  Genetic clade with substitutions (nextflu subgroup)^a^                Alberta   British Columbia   Ontario   Quebec   Overall                                        
  --------------------------------------------------------------------- --------- ------------------ --------- -------- --------- -------- -------- -------- --------- --------
  Influenza A(H3N2)                                                     114       100                38        100      50        100      27       100      229       100
  **Clade 3C.2a**                                                       **105**   **92**             **36**    **95**   **48**    **96**   **24**   **89**   **213**   **93**
  \+ N31S + D53N + R142G + S144R + N171K + I192T + Q197H (subgroup 1)   2         2                  0         0        0         0        1        4        3         1
  \+ N121K + S144K (subgroup 2)^b^                                      1         1                  1         3        3         6        1        4        6         3
  \+ T131K + R142K + R261Q (subgroup 3)^c^                              102       89                 35        92       45        90       22       81       204       89
  **Clade 3C.2a1**                                                      **9**     **8**              **2**     **5**    **1**     **2**    **3**    **11**   **15**    **7**
  \+ N121K + T135K (subgroup 4)^d^                                      2         2                  1         3        0         0        0        0        3         1
  \+ N121K + K92R + H311Q (subgroup 5)^e^                               7         6                  1         3        1         2        3        11       12        5
  **Clade 3C.3a**                                                       **0**     **0**              **0**     **0**    **1**     **2**    **0**    **0**    **1**     **0**
  Influenza B                                                           76        100                83        100      63        100      11       100      233       100
  Yamagata lineage clade 3^f^                                           76        100                82        99       62        98       7        64       227       97
  Victoria lineage clade 1A^g^                                          0         0                  1         1        1         2        4        36       6         33

Sequencing of the haemagglutinin gene was attempted on a subset of available influenza-positive original patient specimens contributing to interim 2017/18 vaccine effectiveness evaluation. Sequencing was successful for 229 of 236 (97%) influenza A(H3N2) specimens and 233 of 246 (95%) influenza B specimens (collection dates: 5 November 2017 to 13 January 2018).

^a^ Subgroup name as assigned by [nextfl[u.org]{.ul}](https://nextflu.org/h3n2/3y/) \[[@r10]\].

^b^ Five of six viruses in this subgroup had additional substitutions T135K (associated with loss of a potential glycosylation site) + R150K + R261Q; the sixth virus had N122D (associated with loss of a potential glycosylation site) + N171D + S262N.

^c^ 44 of 204 (22%) viruses in this subgroup had an additional substitution K92R and 28 of 204 (14%) had A212T.

^d^ All viruses in this subgroup had additional substitutions G78D + Y94H + V182I; two viruses also had N122D (associated with loss of a potential glycosylation site).

^e^ All but two viruses in this subgroup had additional substitutions T135K (associated with loss of a potential glycosylation site) + E62G + R142G; one virus also had N122D (associated with loss of a potential glycosylation site). One of the other two viruses had T135N.

^f^ All but one of the viruses in this subgroup had additional substitutions L172Q + M251V; one virus had M251V without L172Q.

^g^ Five of six viruses in this subgroup had a deletion at position 162--163.
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Virtually all sequenced influenza B viruses were B(Yamagata) clade 3 (227/233; 97%) and all but one had L172Q + M251V non-antigenic site substitutions, the dominant genetic variant circulating globally since 2015 \[[@r11]\]; one virus had M251V without L172Q. Six viruses were influenza B(Victoria) clade 1A (five with a deletion at position 162--163) \[[@r11]\].

Epidemiological findings
========================

Most (64%) participants were adults 20--64-years-old. More influenza B cases (20%) than controls (11%) were children 9--19-years-old (p \< 0.01) ([Table 2](#t2){ref-type="table"}). More cases of influenza A(H3N2) (25%; p = 0.07) and influenza B (27%; p \< 0.01) were 50--64-years-old compared with controls (18%).

###### Participant profile, interim 2017/18 influenza vaccine effectiveness evaluation, Canadian Sentinel Practitioner Surveillance Network, 5 November 2017--20 January 2018 (n = 1,408)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic                                          All participants (column %)   \% vaccinated^a^ (row %)                                                                                                                                              
  ------------------------------------------------------- ----------------------------- -------------------------- --------- ------ ----------- --------- ------- ----------- ------ ------------ --------- ------ ------------- --------- ----- ------------ ---------
  Overall                                                 302                              100                     NA        351       100      NA        719        100      100        33       NA        80         23        NA        253       35       NA

  Age group (years)                                                                                                                                                                                                                                           

  1--8                                                    18                            6                          0.07      21     6           \< 0.01   64      9           2      11           \< 0.01   0      0             \< 0.01   10    16           \< 0.01

  9--19                                                   31                            10                         70        20     82          11        7       23          1      1            15        18                                                

  20--49                                                  126                           42                         117       33     325         45        34      27          21     18           91        28                                                

  50--64                                                  77                            25                         95        27     131         18        26      34          30     32           48        37                                                

  ≥ 65                                                    50                            17                         48        14     117         16        31      62          28     58           89        76                                                

  Median (range)                                          43                            (2--87)                    0.17      43     (1--91)     0.53      39      (1--96)     53.5   (3--87)      \< 0.01   61.5   (12--91)      \< 0.01   52    (1--96)      \< 0.01

  Sex                                                                                                                                                                                                                                                         

  Female                                                  185                           62                         0.45      205    59          0.95      421     59          71     38           0.02      55     27            0.03      162   38           0.04

  Male                                                    115                           38                         143       41     291         41        29      25          24     17           90        31                                                

  Unknown                                                 2                             NA                         NA        3      NA          NA        7       NA          0      NA           NA        1      NA            NA        1     NA           NA

  Co-morbidity^e^                                                                                                                                                                                                                                             

  No                                                      226                           77                         0.57      262    80          0.12      524     76          63     28           \< 0.01   46     18            \< 0.01   155   30           \< 0.01

  Yes                                                     66                            23                         65        20     168         24        33      50          31     48           92        55                                                

  Unknown                                                 10                            NA                         NA        24     NA          NA        27      NA          4      NA           NA        3      NA            NA        6     NA           NA

  Province                                                                                                                                                                                                                                                    

  Alberta                                                 127                           42                         \< 0.01   91     26          0.10      201     28          40     31           0.10      14     15            \< 0.01   75    37           \< 0.01

  British Columbia                                        48                            16                         107       30     200         28        16      33          31     29           70        35                                                

  Ontario                                                 77                            25                         114       32     203         28        33      43          33     29           84        41                                                

  Quebec                                                  50                            17                         39        11     115         16        11      22          2      5            24        21                                                

  Specimen collection interval from ILI onset (days)^f^                                                                                                                                                                                                       

  ≤ 4                                                     239                           79                         \< 0.01   252    72          0.42      499     69          78     33           0.73      58     23            0.87      170   34           0.34

  5--7                                                    63                            21                         99        28     220         31        22      35          22     22           83        38                                                

  Median (range)                                          3                             (0--7)                     \< 0.01   3      (0--7)      0.85      3       (0--7)      3      (0--7)       0.18      3      (1--7)        0.96      3     (0--7)       0.88

  Specimen collection month                                                                                                                                                                                                                                   

  November                                                38                            13                         0.10      23     7           \< 0.01   129     18          6      16           0.04      1      4             0.03      27    21           \< 0.01

  December                                                124                           41                         117       33     269         37        47      38          23     20           99        37                                                

  January                                                 140                           46                         211       60     321         45        47      34          56     27           127       40                                                

  2017/18 vaccination status                                                                                                                                                                                                                                  

  Vaccination without regard to timing^g^                 112/\                         36                         0.48      87/\   24          \< 0.01   285/\   38          NA     NA           NA        NA     NA            NA        NA    NA           NA
                                                          314                                                                358                          751                                                                                                 

  ≥ 2 weeks before ILI onset                              100                           33                         0.52      80     23          \< 0.01   253     35          NA     NA           NA        NA     NA            NA        NA    NA           NA
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ILI: influenza-like illness; NA: not applicable.

The number of participants with unknown sex or comorbidity are shown in table but excluded from the denominator for calculating percentages.

^a^ Vaccination status based on patient and/or practitioner report; defined as receipt of 2017/18 seasonal influenza vaccine ≥ 2 weeks before symptom onset. Patients vaccinated \< 2 weeks before onset or with unknown vaccination status/timing were excluded.

^b^ p value for comparison of influenza A(H3N2) cases to negative controls. Differences were compared using the chi-squared test or Wilcoxon rank-sum test.

^c^ p value for comparison of influenza B cases to negative controls. Differences were compared using the chi-squared test or Wilcoxon rank-sum test.

^d^ p value for comparison of vaccinated participants to unvaccinated participants. Differences were compared using the chi-squared test or Wilcoxon rank-sum test.

^e^ Includes chronic co-morbidities that place individuals at higher risk of serious complications from influenza as defined by Canada's National Advisory Committee on Immunization (NACI), including: heart, pulmonary (including asthma), renal, metabolic (such as diabetes), blood, cancer or immunocompromising conditions, conditions that compromise management of respiratory secretions and increase risk of aspiration, or morbid obesity (body mass index ≥ 40).

^f^ Missing specimen collection dates were imputed as the laboratory accession date minus 2 days, the average time between specimen collection and accession dates among specimens with complete information for both values.

^g^ Participants who received seasonal 2017/18 influenza vaccine \< 2 weeks before ILI onset or for whom vaccination timing was unknown were excluded from the primary analysis. They are included here for assessing vaccination regardless of timing for comparison to other sources of vaccination coverage.

Adjusted VE against influenza A(H3N2) was 17% (95% confidence interval (CI): −14 to 40) overall and 10% (95% CI: −31 to 39) in adults 20--64-years-old ([Table 3](#t3){ref-type="table"}). The corresponding VE against influenza B was higher at 55% (95% CI: 38 to 68) and 40% (95% CI: 10 to 60), respectively. With adjustment by calendar month (rather than 2-week interval) and the same covariates otherwise, VE with restriction to influenza B viruses of known Yamagata lineage (239/351; 68%) was 58% (95% CI: 38 to 71) overall and 47% (95% CI: 16 to 67) in adults 20--64-years-old. Adjusted VE against any influenza A and B combined was 42% (95% CI: 25 to 55) overall and 31% (95% CI: 6 to 49) in adults 20--64-years-old.

###### Interim 2017/18 vaccine effectiveness estimates, Canadian Sentinel Practitioner Surveillance Network, 5 November 2017--20 January 2018 (n = 1,408)

  Model                           Influenza A(H3N2)   Influenza B   Overall (A and B)                          
  ------------------------------- ------------------- ------------- ------------------- ---------- ----------- ----------
  All participants                                                                                             
  Sample size                     n vac / N           \% vac        n vac / N           \% vac     n vac / N   \% vac
  Cases                           100/302             33            80/351              23         186/689     27
  Controls                        253/719             35            253/719             35         253/719     35
  Vaccine effectiveness           VE %                95% CI        VE %                95% CI     VE %        95% CI
  Unadjusted                      9                   −21 to 31     46                  27 to 59   32          14 to 46
  Age group                       15                  −15 to 38     49                  30 to 63   36          18 to 50
  Province                        8                   −23 to 31     49                  31 to 62   34          16 to 47
  Specimen collection interval    8                   −23 to 31     46                  27 to 59   31          14 to 45
  Calendar time                   13                  −16 to 35     52                  35 to 64   38          21 to 51
  Full covariate adjustment^a^    17                  −14 to 40     55                  38 to 68   42          25 to 55
  Participants 20--64 years-old                                                                                
  Sample size                     n vac / N           \% vac        n vac / N           \% vac     n vac / N   \% vac
  Cases                           60/203              30            51/212              24         113/439     26
  Controls                        139/456             30            139/456             30         139/456     30
  Vaccine effectiveness           VE %                95% CI        VE %                95% CI     VE %        95% CI
  Unadjusted                      4                   −37 to 33     28                  −5 to 50   21          −6 to 41
  Full covariate adjustment^a^    10                  −31 to 39     40                  10 to 60   31          6 to 49

CI: confidence interval; n vac: number vaccinated; N: number total; % vac: percentage vaccinated; VE: vaccine effectiveness.

^a^ Analyses adjusted for age group (categorical: 1--8, 9--19, 20--49, 50--64 or ≥ 65 years), province (categorical: Alberta, British Columbia, Ontario or Quebec), specimen collection interval (categorical: ≤ 4 or 5--7 days) and calendar time (categorical: 2-week intervals based on week of specimen collection).

Discussion
==========

In most other interim analyses by the Canadian SPSN, type B viruses comprised less than 10% of influenza detections, whereas in 2017/18, they were identified in an equal proportion with influenza A(H3N2) \[[@r7]-[@r9]\]. Although the reasons for an earlier influenza B onset are unclear, Canada experienced a substantial influenza A(H3N2) epidemic in 2016/17 that may have altered population immunity and the overall 2017/18 influenza A(H3N2) contribution \[[@r9]\].

Nearly all (93%) characterised influenza A(H3N2) viruses were clade 3C.2a, a change from 2016/17 when most (80%) of the A(H3N2) viruses instead belonged to clade 3C.2a1 \[[@r9]\]. Furthermore, a single subgroup of clade 3C.2a with T131K + R142K + R261Q substitutions (i.e. nextflu subgroup 3 \[[@r10]\]) is currently predominating (89% of influenza A(H3N2) viruses), whereas a more heterogeneous mix of genetic variants contributed in Canada during 2016/17 \[[@r9]\] and in Australia during their 2017 epidemic \[[@r5]\]. Changes in the proportionate contribution and emerging predominance of clade 3C.2a variants among circulating influenza A(H3N2) viruses are important to monitor globally. The World Health Organization will decide in February 2018 whether to update the current clade 3C.2a vaccine antigen for the 2018/19 northern hemisphere vaccine, having already chosen a clade 3C.2a1 strain for the southern hemisphere's 2018 vaccine \[[@r4]\].

Our 2017/18 interim VE estimate of 17% (95% CI: −14 to 40) is less than half that reported for the same A(H3N2) vaccine in 2016/17, including interim analyses by the Canadian SPSN (42%; 95% CI: 18 to 59) \[[@r9]\], the US Flu VE Network (43%; 95% CI: 29 to 54) \[[@r12]\] and the European I-MOVE Network (38%; 95% CI: 21 to 51) \[[@r13]\]. Our estimate is also lower than end-of-season estimates from Canada (37%; 95% CI: 20 to 51) \[[@r14]\] and the US (34%; 95% CI: 24 to 42) for 2016/17 \[[@r15]\], and lower than is expected generally for influenza A(H3N2) vaccines (33%; 95% CI: 26 to 39) \[[@r16]\].

Our 2017/18 interim VE for influenza A(H3N2) is more comparable to the 2017 southern hemisphere interim VE of 10% (95% CI: −16 to 31) reported from Australia \[[@r5]\]. Differences in virological and participant profiles, as well as the stage of the epidemic, have to be taken into account when comparing VE estimates across studies. Working-age adults comprised the majority of participants in both studies and the 2017/18 interim VE against influenza A(H3N2) among Canadian SPSN participants 20--64-years-old (10%; 95% CI: −31 to 39) is also comparable to the 2017 estimate reported from Australia for 15--64-year-olds (16%; 95% CI: −11 to 36). Sample size for other age groups (e.g. children, elderly adults) was too limited to derive reliable interim estimates or to inform protection in specific high-risk groups.

All influenza vaccine manufacturing in Canada is egg-based. Mutations that arise from egg adaptation of the vaccine strain may affect VE, an issue also identified for the current season's A(H3N2) vaccine component \[[@r17],[@r18]\]. In Canada this season, antigenic characterisation of influenza A(H3N2) viruses has only been presented in relation to a cell-propagated version of the vaccine reference strain; characterisation against an egg-based version has not been reported \[[@r1]\]. Among the small subset of Canadian viruses that could be successfully characterised, all were considered antigenically similar to the cell-propagated vaccine strain \[[@r1]\]. Conversely, where relatedness to the egg-propagated version of the vaccine strain has been specifically explored elsewhere, more variability has been identified, with a greater proportion of viruses considered antigenically distinct from the egg-propagated version \[[@r5],[@r11],[@r19]\].

We found higher VE of 55% (95% CI: 38 to 68) against influenza B despite prominent use of TIV containing a B(Victoria) antigen that was lineage-mismatched to almost exclusively B(Yamagata) viruses. Approximately 70% of vaccine doses distributed in SPSN provinces during the 2017/18 season were TIV, albeit with regional variation that will be explored in end-of-season analyses. Substantial cross-lineage VE for influenza B has been observed previously \[[@r20]\], including during the prior 2016/17 season in Canada when VE against lineage-mismatched influenza B using the same B(Victoria) TIV component was 73% (95% CI: 52 to 84) \[[@r14]\] and QIV comprised an even smaller proportion (\< 25%) of vaccine doses distributed. Our estimate for the current season is comparable to the interim VE of 57% (95% CI: 41 to 69) for influenza B reported from Australia, despite exclusive use of QIV in that country \[[@r5]\].

Other agent--host and immuno--epidemiological interactions, including birth cohort effects induced by differential prime--boost exposures, may also play a role in VE \[[@r21]\]. The effect of prior vaccination history was not assessed here owing to sample size limitations, but will be explored as part of the end-of-season analyses.

Conclusions
===========

As reported from Australia for the 2017 southern hemisphere vaccine, interim estimates from Canada for the 2017/18 northern hemisphere vaccine indicate low VE of less than 20% against influenza A(H3N2), notably among working-age adults. While the influenza A(H3N2) epidemic continues, adjunct protective measures should be reinforced to minimise the associated disease burden in high-risk individuals \[[@r22]\]. Interim 2017/18 VE estimates against influenza B are higher at 55% despite prominent TIV use, suggesting cross-lineage protection.
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